Summary
Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) and the Guillain-Barré syndrome are polyneuropathies of presumed autoimmune aetiology. Despite the availability of improved therapeutic options, both diseases may still carry a grave prognosis with sustained disability (Winer et al., 1988; Hartung et al., 1995) . Whereas Guillain-Barré syndrome is easily diagnosed on clinical and electrophysiological grounds, diagnosis of CIDP may be more challenging if clinical findings and auxiliary tests, including sural biopsy findings, are equivocal. However, correct diagnosis is crucial as immunomodulatory and immunosuppressive therapies for CIDP may be useless or even harmful for patients with noninflammatory neuropathies.
Direct histopathological documentation of inflammatory
© Oxford University Press 1998 of labelled endoneurial cells revealed significantly elevated cell counts compared with controls. In individual biopsies, elevated levels of one differentiation antigen were not necessarily associated with high expression of the other antigens, pointing to functional heterogeneity of endoneurial macrophages. Endoneurial cell counts for at least one of the differentiation markers that were greater than in any of the non-inflammatory control nerves were found in two-thirds of all inflammatory biopsies, whereas T-cell counts and in particular total macrophage counts were less sensitive in picking up biopsies from patients with inflammatory neuropathies. Antibodies to macrophage differentiation antigens are additional simple and helpful diagnostic tools in differentiating autoimmune from non-inflammatory neuropathies in sural nerve biopsies.
infiltrates has been achieved in a multitude of studies of Guillain-Barré syndrome and CIDP sural nerve biopsies (Pollard et al., 1986 (Pollard et al., , 1987 Cornblath et al., 1990; Schmidt et al., 1996) . However, T cells may be absent in some of these biopsies. Conversely, they may be present in noninflammatory conditions, limiting their diagnostic value (Hughes et al., 1992; Gabreels-Festen et al., 1993; Said et al., 1994; Schmidt et al., 1996) . Macrophages have attracted particular attention as they appear to be instrumental as effector cells in immune-mediated demyelination (Hartung et al., 1988) . They may penetrate seemingly intact myelin sheaths and strip myelin from the axonal surface (Prineas, 1972; Prineas and McLeod, 1976) in addition to elaborating cytotoxic compounds and immunoregulatory molecules such as cytokines (Hartung et al., 1996) . Endoneurial infiltration by macrophages also occurs, however, in Wallerian degeneration (Griffin et al., 1992) . As a result, assessment of macrophage infiltration using conventional pan-macrophage markers provides little help in differential diagnosis. Furthermore, relatively little is known about differential functional characteristics of endoneurial macrophages in immune-mediated demyelination. Recently, an investigation of macrophage differentiation during CNS demyelination in multiple sclerosis, using a panel of novel inflammation-associated macrophage differentiation antigens, revealed a striking heterogeneity of macrophages depending on the stage of the multiple sclerosis lesions (Brück et al., 1995) . Here we hypothesize that endoneurial macrophages may also be immunophenotypically heterogeneous in demyelinating autoimmune polyneuropathies, and that the recognition of patterns of macrophage subsets in sural nerve biopsies may aid in differentiating autoimmune from degenerative polyneuropathies.
Patients
Sural nerve biopsies were obtained from 76 patients after informed consent for diagnostic analysis under a research protocol. The demographic and clinical characteristics of the patients are summarized in Table 1 . Twenty biopsies were taken from patients with Guillain-Barré syndrome, as diagnosed according to accepted research criteria (Asbury and Cornblath, 1990) , all but one patient being scheduled on a treatment trial protocol. Biopsies were taken at different intervals after disease onset (3-25 days) and different stages of the disease (two patients during progression, eight during the early plateau stage, six during the late plateau, four during early recovery). Maximum disease severity was grade 3 in two patients, grade 4 in 16 patients and grade 5 in another two patients (Guillain-Barré Syndrome Steroid Trial Group, 1993) . All patients had the demyelinating form of the disease, with variable degrees of secondary axonal involvement with disease progression. All patients but one were treated with immunoglobulins, plasma exchange or both, starting between 1 and 11 days before biopsy. Twenty-three biopsies were taken from patients with CIDP according to accepted research criteria (Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force, 1991) with minor modifications. Thus, definite CIDP was diagnosed in 16 patients with a chronic progressive or relapsing-remitting, distal-symmetrical motor or sensorimotor polyneuropathy, tibial nerve conduction velocities ഛ35 m/s (range, 23-35 m/s), CSF total protein content Ͼ60 mg/dl (range, 62-422 mg/dl), and signs of a demyelinating neuropathy on sural nerve biopsy. Three of these patients were treated with glucocorticoids at the time of biopsy. In all of these cases other potential causes of the neuropathy were excluded. Five additional patients (one receiving glucocorticoids) fulfilled the diagnostic criteria for CIDP but had underlying diseases including diabetes mellitus (two patients), lymphoma (two patients) and chronic infection (one patient). Two patients diagnosed as probably having CIDP fulfilled all diagnostic criteria except that marked nerve conduction slowing was found only in sensory nerve conduction studies.
Sixteen biopsies (other inflammatory neuropathies) were taken from patients with definite neuroborreliosis (three cases), inflammatory polyneuropathy of unknown cause as evidenced from massive T-cell infiltration of the peripheral nerve (four cases), purely sensory symptoms in combination with a demyelinating neuropathy and elevated CSF protein (six cases, three of them with mild diabetes mellitus, mental retardation with epilepsy, and multiple sclerosis treated with glucocorticoids, respectively), and a relapsing-remitting polyneuropathy with a previously good response to glucocorticoid treatment (three cases).
Apart from the cases specified, none of the patients had received any kind of immunosuppressive or immunomodulatory treatment within the last 3 months before biopsy.
Twelve sural nerve biopsies served as non-inflammatory disease controls, with definite diagnoses of various hereditary polyneuropathies, including hereditary neuropathy with liability to pressure palsy (four cases), hereditary motor and sensory neuropathy I (three), hereditary motor and sensory neuropathy II (three), hereditary sensory neuropathy (one) and mitochondrial neuropathy (one). Five biopsies taken from the files were from normal nerves without clinical or morphological evidence of neuropathy, which were obtained because of suspected lipid storage disease, cerebral vasculitis and atypical amyotrophic lateral sclerosis.
The study was approved by the ethics committee of the University of Würzburg.
Material and methods
Sural nerve segments were fixed in 4% buffered paraformaldehyde and embedded in paraffin. Paraffin sections 5 µm thick were dewaxed, rehydrated and pretreated with either 0.4 mg/ml protease type XXIV (Sigma, Deisenhofen, Germany) for 7 min at 37°C (anti-macrophage antibodies) or 1 mg/ml hyaluronidase type III (Sigma) in 100 mM sodium acetate (pH 5.5), 150 mM sodium chloride for 30 min at room temperature (anti-T-cell antibody). Primary antibodies were applied overnight at 4°C as follows: KiM1P, recognizing all macrophages, 1 : 1000, a generous gift of Dr H. J. Radzun, Göttingen (Radzun et al., 1991) ; MRP14, recognizing early activated macrophages, 1 : 400 (Dianova, Hamburg, Germany) (Odink et al., 1987) ; 27E10, recognizing early activated macrophages, 1 : 100 (Dianova) (Zwadlo et al., 1986) ; 25F9, recognizing inflammatory macrophages late during inflammation, 1 : 50 (Dianova) (Zwadlo et al., 1985) ; MRP8, recognizing inflammatory macrophages late during inflammation, 1 : 50 (Dianova) (Odink et al., 1987) ; anti-CD3, recognizing T cells, 1:200 (Nova Nordisk, Hamburg, Germany). Antibody detection was by sequential application of a secondary biotinylated polyclonal anti-mouse IgG antibody (Dako, Hamburg, Germany), avidin-biotinylated peroxidase complex (Dako), and 3,3Ј-diaminobenzidine (Sigma) as chromogen in the presence of hydrogen peroxide. Sections were counterstained with haematoxylin.
Endoneurial labelled macrophages were counted under ϫ100 oil immersion in at least 10 microscopic fields of 100ϫ100 µm. To test for local variations in the macrophage antigen expression patterns, results obtained from sections cut from different paraffin blocks were compared in five biopsies. Variation was Ͻ10% for all macrophage markers throughout. Therefore, only sections from one single plane taken as representative were quantified subsequently. Endoand epineurial T cells were counted across an entire transverse section of each biopsy, and their numbers were related to the endo-and epineurial area determined on digitized images. Only immunoreactivity associated with a cell nucleus was accepted. Data are given as cells/mm 2 .
Statistical analysis was performed using the Spearman rank correlation and the Mann-Whitney test for comparison between pairs of individual groups.
Results

T cells and KiM1P-positive macrophages
To obtain baseline information on inflammatory infiltrates in the present biopsy material, we first re-analysed endo-and epineurial T-cell infiltrates and the total number of endoneurial macrophages using an anti-CD3 antibody for T cells and the KiM1P antibody recognizing all macrophages.
Epineurial T-cell counts were significantly elevated in inflammatory biopsies compared with normal and hereditary neuropathy disease controls, with peak counts up to 12-fold above the highest control value (Fig. 1) . Endoneurial T cells were also highly elevated in some of the Guillain-Barré syndrome and CIDP biopsies but not in others when compared with normal and non-inflammatory disease controls, with Fig. 1 Density of epi-and endoneurial T cells and endoneurial macrophages labelled with the pan-macrophage marker KiM1P in biopsies from patients with Guillain-Barré syndrome (GBS, n ϭ 20), chronic inflammatory demyelinating polyneuropathy (CIDP, n ϭ 23), other inflammatory neuropathies (OIN, n ϭ 16), hereditary neuropathies (HN, n ϭ 12) and normal nerves (N, n ϭ 5). Box and whisker plot. The central horizontal bar denotes the median value, the top and bottom lines of the box denote the 75th and 25th percentiles, respectively, the top and bottom ends of the error bar denote the 95th and 5th percentiles, and the top and bottom filled circles denote the highest and lowest values. The arithmetic mean is represented by the filled circle in the middle of the column. Note that not all lines and circles are visible, because of overlap. ***P Ͻ 0.001, **P Ͻ 0.01, *P Ͻ 0.05; ns, not significant, comparing the respective disease groups with hereditary neuropathy and normal cases (Mann-Whitney test).
peak counts more than five-and nine-fold above the highest control. However, the differences reached statistical significance only when comparing Guillain-Barré syndrome with hereditary neuropathy nerves (Fig. 1) . Significantly elevated endoneurial T-cell counts compared with both hereditary neuropathies and normal controls were also found in biopsies Representative immunocytochemical stains with anti-macrophage antibodies KiM1P (A-C; all macrophages), MRP14 (D-F; early inflammatory macrophages), MRP8 (G-I; chronic inflammatory macrophages) and 25F9 (J-L; chronic inflammatory macrophages) in sural nerve biopsies from a patient with severe Guillain-Barré syndrome (A, D, G, J; early plateau phase, 13 days after disease onset), CIDP (B, E, H, K; 3 years disease duration), and a non-inflammatory control case with hereditary neuropathy with liability to pressure palsy (C, F, I, L). Whereas endoneurial macrophages were abundantly present in all cases, only a few MRP14-positive cells and no 25F9 and MRP8 antigens were found in the control case, with markedly elevated expression in the Guillain-Barré syndrome and CIDP cases. Brown immunocytochemical reaction product, sections counterstained with haematoxylin. Microphotographs, magnification ϫ160.
from other inflammatory neuropathies, with peak values ninefold above the highest control.
KiM1P-positive endoneurial macrophages were significantly more frequent in hereditary neuropathies compared with normal controls. Even greater numbers were found in inflammatory disease groups, with cell counts significantly higher than both in hereditary neuropathies and normal control nerves (Figs 1 and 2 ). However, there was wide variation in total macrophage counts even within the same disease group, and considerable overlap between values obtained from inflammatory and hereditary neuropathies. Qualitatively, KiM1P-positive macrophages in inflammatory conditions were generally more heavily labelled and were larger in size than in hereditary neuropathies and normal controls.
The findings are consistent with previously published studies on inflammatory infiltrates in Guillain-Barré syndrome and CIDP (Pollard et al., 1986 (Pollard et al., , 1987 Cornblath et al., 1990; Hughes et al., 1992; Gabreels-Festen et al., 1993; Said et al., 1994; Schmidt et al., 1996) .
Analysis of macrophages carrying inflammation-associated antigens
Strong immunoreactivity for one or more of the inflammatory macrophage markers MRP14, 25F9 and MRP8 was found in several but not all nerves from patients with Guillain-Barré syndrome, CIDP or other inflammatory neuropathies (Fig. 2) . In contrast, immunoreactive macrophages were only rarely seen in nerves from patients with hereditary neuropathies and hardly occurred at all in normal control nerves. Immunoreactivity for 27E10 was never found in such nerves. In inflammatory biopsies, labelled macrophages were also more intensely stained compared with control nerves and were usually more prevalent within the endoneurium than epineurially. Considerable differences in staining patterns between individual biopsies were noted even within the same disease group, some biopsies expressing one but not another marker and other biopsies showing reciprocal results.
To obtain better insight into the frequency of macrophages expressing inflammation-associated antigens in the various disease groups, labelled endoneurial macrophages were quantified in each nerve (Fig. 3A) . Only low numbers of MRP14-, 25F9-and MRP8-positive macrophages were found in normal and disease control nerves. No significant differences for any of the four markers were found between hereditary neuropathies and normal nerves. In contrast, the number of 25F9-and MRP8-positive macrophages was significantly elevated in inflammatory biopsies compared with normal and disease controls, with peak values 10-to 20-fold above the highest control counts. However, as described for the KiM1P-positive total macrophage counts, there was again great variation in the number of labelled cells within the disease groups, but overlap between inflammatory and non-inflammatory disease groups was much less for 25F9-and MRP8-positive macrophages than for KiM1P-positive macrophages. Macrophages carrying the more acute inflammatory macrophage markers MRP14 and 27E10 were also elevated in inflammatory biopsy groups compared with disease controls. MRP14-positive cells were elevated up to eight-fold above the highest control count, and were significantly more frequent in Guillain-Barré syndrome and other inflammatory neuropathies compared with hereditary neuropathies. 27E10-positive cells were generally less frequent, but again significantly elevated in all inflammatory disease groups compared with hereditary neuropathies. As for the other macrophage markers, there was great variation in cell counts within the groups, with little or no increase of cell counts in some biopsies, resulting in little (MRP14) or no (27E10) change in median values compared with hereditary neuropathy disease controls and normal nerves.
Further insight was gained by considering macrophage subpopulations in individual biopsies and groups of biopsies and comparing the staining patterns for each of the differentiation antigens. Although there was an overall statistical correlation between the occurrences of the various macrophage differentiation antigens with each other and the total number of macrophages (Table 2) , no consistent pattern of specifically labelled cells could be found in individual biopsies. Within each of the major inflammatory disease groups individual biopsies were found where the cell counts for one but not another, two, all or none of the differentiation antigens were elevated to a significant degree, pointing to a considerable heterogeneity of endoneurial macrophages (data not shown).
As differences in cell counts for macrophages carrying macrophage differentiation antigens may merely reflect differences in the total number of macrophages in individual biopsies, the percentage of cells carrying such antigens was calculated with reference to the entire macrophage population detected by KiM1P, and the above analysis was repeated using the values obtained. Essentially similar results were obtained, with strong increases in the percentage of macrophages carrying inflammatory macrophage antigens in some of the inflammatory biopsies compared with the noninflammatory controls (Fig. 3B) .
In addition, macrophage and T-cell counts may have been influenced by associated medical conditions or glucocorticoid treatment that occurred in small subgroups of the biopsies. Therefore, the above data were reanalysed considering the various subgroups separately and after omission of such biopsies. There was no indication of an influence of these variables on the results presented above (data not shown).
Sensitivity and specificity of inflammatory macrophage differentiation antigens and T cells in detecting inflammatory neuropathies
To obtain information on whether staining for inflammatory macrophage antigens might be a sensitive and specific test for the diagnosis of inflammatory neuropathies, the number of such biopsies that contained immunoreactive cell counts above the highest count obtained from any of the normal and disease controls was determined (Fig. 4) . Total macrophage counts were not helpful in differentiating All inflammatory neuropathies are considered together (n ϭ 59). ***P Ͻ 0.001, **P Ͻ 0.01; *P Ͻ 0.05; n.s., not significant (Spearman rank correlation).
Fig. 4
Percentage of biopsies with cellular densities of T cells, KiM1P-positive endoneurial macrophages and endoneurial macrophages carrying macrophage differentiation antigens that exceeded the highest cell count found in any of the hereditary neuropathy disease control and normal control cases. Using macrophage differentiation markers, more cases with Guillain-Barré syndrome (GBS) and CIDP are differentiated from controls than using T-cell and pan-macrophage markers. Abbreviations as in Fig. 1 .
between inflammatory conditions and normal and disease controls as only ഛ10% of the inflammatory biopsies carried macrophage numbers in excess of the highest control value. Endo-or epineurial T-cell counts above any of the control values were found in only 35% of CIDP cases and 25% of Guillain-Barré syndrome cases. In contrast, cell counts for 25F9-positive macrophages above any control value were found in nearly 60% of CIDP cases and 45% of GuillainBarré syndrome cases. At least one of the inflammatory macrophage markers was found to be elevated beyond any of the control values in 70% of CIDP cases and 55% of Guillain-Barré syndrome cases, whereas total macrophage or T-cell counts above any of the control counts were found in Ͻ40% of CIDP cases and 45% of Guillain-Barré syndrome cases. In the group with other inflammatory neuropathies the advantage of macrophage differentiation markers was less striking despite high levels of antigen expression, as high Tcell counts were found in many of these biopsies, forming an entry criterion to the group for some. Using all macrophage and T-cell antibodies together, 74% of CIDP cases, 55% of Guillain-Barré syndrome cases and 87% of cases of other inflammatory neuropathies had cell counts above the highest value in any of the normal or disease controls for at least one of the markers.
Correlation of individual patterns of inflammatory macrophages with clinical and histological criteria
As the presence of putative early and late inflammatory macrophage antigens might reflect the pathological stage of the inflammatory neuropathological process and different functional states of these cells, the numbers of labelled macrophages were correlated with each other, the number of infiltrating T cells and various clinical criteria. Considering all inflammatory biopsies together, a significant positive correlation was found between the respective cell counts for each of the inflammatory antigens (Table 2) , i.e. biopsies with macrophages immunoreactive for one inflammatory antigen are likely to contain macrophages expressing any other inflammatory antigen. However, as pointed out above, this was not necessarily true at the level of individual biopsies. Cell counts for MRP14-, 25F9-and MRP8-positive endoneurial macrophages were positively and significantly correlated with the numbers of endo-and epineurial T cells, whereas 27E10-positive macrophages were not. The presence of MRP14-, 27E10-and MRP8-positive macrophages was significantly correlated with a more recent onset of the inflammatory neuropathological process, but this correlation was weak (Table 2) . When Guillain-Barré syndrome biopsies were considered separately, no correlation between the duration of the disease at the time of biopsy and the numbers of cells labelled with any of the antibodies investigated, including T cells, could be established. Also, no convincingly significant correlation was found between the density of macrophages carrying inflammation-related antigens and the degree of electrophysiological and histological involvement of the biopsied sural nerves, although higher cell counts for any of the inflammatory antigens were generally associated with more severe disease.
Discussion
Sural nerve biopsies are taken in cases of undiagnosed neuropathies frequently with the specific diagnostic purpose of investigating the inflammatory nature of the condition. Positive results have immediate clinical consequences as inflammatory neuropathies are amenable to effective therapies (Toyka and Hartung, 1996) . In our present study, we provide evidence that macrophage differentiation antigens might be useful additional diagnostic markers with which to differentiate between potentially treatable autoimmune neuropathies and other conditions which are often untreatable. In~70% of our CIDP cases, at least one of the differentiation markers was expressed at levels significantly above control values whereas T-cell immunohistochemistry could detect significantly elevated cell counts in only~40% of the biopsies. Macrophage differentiation markers thus appear to provide a more powerful diagnostic tool than antibodies against T cells. Essentially similar results were found in our GuillainBarré syndrome cases, although here sural nerve biopsy is usually not necessary in order to make the diagnosis. In the other inflammatory neuropathies group, the diagnostic yield of macrophage markers was as strong as in the other groups but the advantage over T-cell stains was less obvious, mainly because of already high numbers of endo-and epineurial T cells in this group. However, as with T-cell and panmacrophage markers, the distinction is not absolute and some overlap exists. Furthermore, we have no information on antigenic macrophage properties in massive macrophage responses following fulminant toxic or traumatic axonal degeneration, as such nerves are usually not taken for biopsy.
Macrophages are crucial components in the pathogenetic interplay of cellular and humoral immune mechanisms during the development of autoimmune neuropathies (Griffin et al., 1993) . In addition to investigations of human nerve tissue, much has been learned from animal studies in EAN (experimental allergic neuritis), where macrophages are essential sources of cytotoxicity, myelin and tissue degradation, and cytokine secretion (Hartung et al., 1996) . In the present study we demonstrate that endoneurial macrophages can express additional cellular differentiation markers in human inflammatory and autoimmune polyneuropathies.
MRP8 and MRP14 are calcium-binding proteins expressed in blood monocytes and granulocytes which are transiently and selectively expressed in tissue macrophages during early stages of differentiation but are absent from mature resident tissue macrophages (Dorin et al., 1987; Odink et al., 1987; Andersson et al., 1988; Lagasse and Clerc, 1988; Hogg et al., 1989) . Histological studies have revealed nearly exclusive expression of these antigens under inflammatory conditions, MRP8 being more prevalent in chronic than in acute inflammatory situations (Odink et al., 1987) . Similarly, the 27E10 antigen, which is formed by heterodimerization of MRP8 and MRP14 (Bhardwaj et al., 1992) , occurs only in acutely inflamed tissues and is virtually absent in chronic inflammation and non-inflammatory lesions (Zwadlo et al., 1986) . The expression of MRP8, MRP14 and 27E10 antigens in nerve biopsies from patients with CIDP and GuillainBarré syndrome thus underlines the inflammatory nature of these conditions and points to a functional differentiation of endoneurial macrophages in autoimmune neuropathy similar to that in other inflammatory conditions. In contrast, the 25F9 antigen appears to be associated with well-differentiated tissue macrophages both in normal and diseased tissue independently of the presence or absence of inflammation (Zwadlo et al., 1985) . However, resident endoneurial macrophages in normal nerves and macrophages in hereditary neuropathies express little or no 25F9 antigen while large numbers of 25F9-positive macrophages are found in nerves of patients with CIDP, Guillain-Barré syndrome and other inflammatory neuropathies. Macrophages are thus phenotypically different between autoimmune and hereditary neuropathies also with respect to the 25F9 antigen.
Although the macrophage antigens investigated in our study are statistically correlated with each other in terms of their expression, this correlation is not absolute. In individual biopsies, macrophages carrying one antigen may be much more prevalent than macrophages carrying another, with reciprocal values found in other biopsies. Furthermore, increased levels of macrophages carrying one or more differentiation markers are not due solely to increases in total macrophage counts. Thus, macrophage populations in autoimmune neuropathies are heterogeneous and the antigens under study appear to be regulated independently. Although functional heterogeneity of macrophages is well known in humans, mice and rats (Hogg, 1987; Gordon et al., 1988; Dijkstra and Damoiseaux, 1993) , it has been poorly documented in peripheral nerve, and its regulation and functional consequences are unknown. The 27E10 antigen is known to be upregulated by interferon-γ (Zwadlo et al., 1986) , and interferon-γ-secreting inflammatory T cells may induce this phenotype in Guillain-Barré syndrome and CIDP nerves. It has also been shown that the soluble form of the 27E10 antigen is increased in the serum of Guillain-Barré syndrome patients prior to plasma exchange (Hetland et al., 1992) . Changes in extracellular matrix composition may also account for phenotype differentiation (Mahnke et al., 1995) . On the other hand, 27E10-positive macrophages in vitro show elevated levels of tumour necrosis factor-α and interleukin 1β secretion compared with 27E10-negative controls (Bhardwaj et al., 1992) , and subcellular redistribution of the heterodimer in response to extracellular matrix components is accompanied by alterations in interleukin 6, tumour necrosis factor-α and superoxide secretion (Mahnke et al., 1995) . In the diseased peripheral nerve, this might have immediate consequences for the inflammatory regulatory cascade, disease progression and myelin breakdown. However, direct evidence is still lacking that certain functions, such as phagocytosis and the expression of cytokines and costimulatory molecules, can be assigned to antigenically defined macrophage subpopulations in peripheral nerves.
Another point of uncertainty is whether these observations reflect regulatory events in extrinsic haematogenous macrophages infiltrating the diseased peripheral nerve or are due to activation of resident endoneurial macrophages. The peripheral nerve harbours a population of endogenous resident macrophages (Griffin et al., 1993) which account for up to 9% of all cells in normal peripheral nerve and appear to constitutively express major histocompatibility complex class II molecules (Bonetti et al., 1993) . However, their function is only poorly understood as they are overwhelmed by extrinsic macrophages in most experimentally induced peripheral nerve lesions. Their CNS counterpart, the resident microglial cell, becomes activated rapidly in many disease states and in response to a multitude of experimental lesions (Gehrmann et al., 1995) . The 27E10 antigen, MRP14 and the 25F9 antigen have all been described on activated microglia in the brain (Akiyama et al., 1994; Verbeek et al., 1995) . It is thus conceivable that some of the macrophage subgroups observed in the present study were derived from reactive endoneurial macrophages rather than from infiltrating haematogenous macrophages. There is, however, evidence from studies in other disease models that the 27E10 antigen is expressed by macrophages recently recruited from the blood (Rugtveit et al., 1996) .
Macrophage differentiation antigens have been used to stage inflammatory lesions in various organs. In multiple sclerosis lesions, 27E10-and MRP14-positive macrophages were associated with early active lesions, whereas 25F9-and MRP8-positive macrophages were found preferentially in chronic and remyelinating lesions (Brück et al., 1995) . Indeed, 27E10-and MRP14-positive macrophages are generally thought to be associated with more acute inflammation, whereas MRP8 and 25F9 occur more frequently in chronic lesions (Zwadlo et al., 1985 (Zwadlo et al., , 1986 Odink et al., 1987) . In our study an overall correlation was found between the duration of disease and the numbers of MRP8-, MRP14-and 27E10-positive macrophages in that these markers were more frequently expressed in patients with recent onset of disease. The presence of these markers may thus point towards active and progressive disease. However, the association was relatively weak and could not be confirmed in Guillain-Barré syndrome cases, where the disease course can be easily defined. This apparent discrepancy is most likely due to the sural nerve not being sufficiently representative, as Guillain-Barré syndrome affects motor nerves more prominently than sensory nerves and inflammation may be most prominent in the nerve roots. In an autopsy study of a patient with severe Guillain-Barré syndrome who died 3 days into the disease from an unrelated cause, we found massive numbers of MRP14-, MRP8-, 27E10-and 25F9-positive macrophages in spinal roots at various segmental levels, also ruling out variable compositions of macrophage populations in different lesions. Thus, despite these drawbacks the composition of endoneurial macrophage subgroups, as detected by our markers, may well be indicative of the activity of the disease process at the site of biopsy and may provide an additional clue for therapeutic decisions. Taken together, and with the caveats mentioned above in mind, our results indicate that the macrophage antigens MRP14, MRP8, 27E10 and 25F9 might be simple and useful diagnostic tools for the evaluation of sural nerve biopsies with greater diagnostic power than conventional macrophage and T-cell markers in differentiating autoimmune from non-inflammatory neuropathies. Routine application of these antibodies may provide additional diagnostic clues and may put therapeutic decisions on firmer grounds.
